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Analysis of parameters associated with hypotension
requiring vasopressor support after carotid
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Brian De Rubertis, MD, Nicholas J. Morrissey, MD, James McKinsey, MD, K. Craig Kent, MD,
and Peter L. Faries, MD, New York, NY
Introduction: Systemic hypotension has been observed for up to 36 hours in response to stimulation of the carotid
baroreceptor by carotid angioplasty and stenting (CAS). The aim of this study was to identify risk factors and cardiac
outcomes for postprocedural hypotension requiring vasopressor support after CAS.
Methods: Between 2003 and 2005, 143 patients (87 men; mean age, 75 years) with high-grade carotid artery stenosis
(mean, 87.3%) were treated with CAS and prospectively entered into a vascular registry. Data were retrospectively
analyzed to determine factors predictive of hypotension requiring vasopressor support after CAS. Atropine and
appropriate intravenous crystalloid solution were administered during CAS. For the first 30 patients, atropine was only
used for symptomatic patients but then became routine and was used for all patients with primary carotid stenosis.
Hypotension (systolic blood pressure <90 mm Hg or a mean arterial blood pressure <50 mm Hg) unresponsive to
conservative measures was treated with vasopressors (phenylephrine or norepinephrine). Patients were stratified into
three groups based on hypotension requiring vasopressors: (1) no vasopressors, (2) vasopressors for <24 hours (short
duration), and (3) vasopressors for>24 hours (prolonged duration). Risk factors for hypotension requiring vasopressors
were analyzed by univariate and multivariate logistic regression analysis.
Results: Postprocedural hypotension requiring vasopressor treatment was seen in 16 (11%) of 143 of patients, with 6 (4%)
requiring vasopressor support for >24 hours. Mean duration of vasopressor administration for all patients was 17  10
hours (range, 6 to 36 hours). By univariate analysis, a history of a previous myocardial infarction (P  .02) or use of the
PercuSurge occlusion balloon (P .05) were both associated with increased incidence of short duration (<24 hours) use
of vasopressors, and female sex (P  .03) and age >80 years old (P  .02) were associated with prolonged (>24 hours)
vasopressor requirement. On multivariate analysis adjusted for age and sex, a history of myocardial infarction (odds ratio
[OR], 4.1; 95% confidence interval [CI], 1.0 to 16.4; P  .05) remained an independent predictor of short-duration
vasopressors. On multivariate analysis, female sex (OR, 10.9; 95% CI, 1.2 to 100.4; P .04) and age>80 years old (OR,
13.8, 95% CI, 1.5 to 127.2; P  .02) remained independent predictors of prolonged vasopressor use. The incidence of
periprocedural myocardial infarctions, arrhythmias, or congestive heart failure did not differ between those patients who
did not receive vasopressors (5/127) and those who received vasopressors for a short (<24 hours) duration (1/10, P 
NS) or prolonged (>24 hours) duration (0/6, P  NS).
Conclusion: Prolonged hypotension requiring vasopressor support occurs in a minority of patients after CAS, with higher
incidences in older women. In contrast, hypotension requiring a more limited duration of vasopressor use occurs more
commonly in patients who had a prior myocardial infarction, independent of age or sex. In this cohort of patients,
vasopressors required for hypotension were not associated with an increased incidence of periprocedural cardiac
complications. Despite the increased incidence of prolonged hypotension in older women, this study demonstrates that
CAS can be performed without an increase in cardiac morbidity in older women. (J Vasc Surg 2006;43:714-20.)Carotid angioplasty and stenting (CAS) is increasingly
being performed as an alternative to carotid endarterec-
tomy (CEA) for the treatment of carotid artery stenosis.
Hemodynamic instability following CEA has been ob-
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714served in 12% to 54% of cases.1,2 This postoperative hemo-
dynamic instability after CEA is associated with increased
rates of neurologic and cardiac complications.2-5 Persistent
hypotension following CAS has been reported in 7% to 34%
of cases, but the factors that necessitate vasopressor utiliza-
tion during CAS have not be defined fully.6,7 The aim of
this study was to identify risk factors and cardiac outcomes
associated with postprocedural hypotension requiring va-
sopressors after CAS.
METHODS
Demographics. From January 2003 to January 2005,
143 patients (87 men; mean age, 74.5 years) with carotid
artery stenosis were treated with CAS at one institution. In
80% of the patients, the procedure was performed as part
of an industry-sponsored trial. Data were prospectively
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proved by the Institutional Review Boards of the Cornell
University, Weill Medical School and Columbia University,
College of Physicians and Surgeons. The analysis of this
data was done retrospectively.
Preoperative patient demographic data are listed in
Table I. Procedural details recorded included heart rate,
blood pressure, medications given, degree of stenosis, size of
native vessel, side of procedure, stent type and size, protection
device used, and angioplasty balloon size. The postproce-
dural data collected included heart rate, blood pressure,
medications, cardiac enzymes, electrocardiogram (ECG)
changes, perioperative and 30-daymorbidity andmortality,
and length of stay.
Hypotension was defined as a systolic blood pressure
90 mm Hg or a mean arterial blood pressure (MAP) of
50 mm Hg. Vasopressor treatment was initiated in the
absence of bleeding, hypovolemia, or acute heart failure.
The primary end point for this study was hypotension that
required vasopressors after CAS. Secondary end points
were periprocedural (24 hours of surgery) cardiac com-
plications. Cardiac complications included new arrthymias
(atrial fibrillation, ventricular tachycardia, asystole, and new
bundle branch block), myocardial infarction (ECG changes
in association with an elevation of cardiac enzymes), or
clinical evidence of congestive heart failure. Patients were
Table I. Demographics (N  143)
N %
Age
Mean  standard deviation 74.5  9.8
Sex
Male 87 64%
Female 56 41%
Pre-operative neurological symptoms 40 29%
Transient ischemic attack 21 15%
Amaurosis fugax 8 6%
Recent stroke 9 7%
Cardiac co-morbidities
Previous myocardial infarction 37 27%
Hypertension 126 92%
Hypercholesterolemia 96 70%
CAD 91 66%
CAD requiring coronary procedure 5 4%
Aortic stenosis 10 7%
Peripheral vascular disease 36 26%
Diabetes mellitus 39 28%
Chronic renal insufficiency 14 10%
Current or previous smoking history 84 61%
Beta blockers 39 28%
Calcium channel blockers 26 19%
High risk criteria
Age 80 y.o. 48 35%
Prior ipsilateral CEA or CAS 22 16%
Neck irradiation 6 4%
Contralateral occlusion 17 12%
Moderate-high cardiac risk 126 92%
Severe COPD 18 13%
CAD, coronary artery disease; CEA, carotid endarterectomy; CAS, carotid
angioplasty and stenting.stratified into three groups based on hypotension requiring(1) no vasopressors, (2) vasopressors for 24 hours, (3)
vasopressors for 24 hours. Only patients who received
vasopressors 2 hours from the end of their procedure
were included in the analysis.
A noninvasive study (either magnetic resonance an-
giography or duplex velocity measurements) was com-
pleted before angiography. The final degree of stenosis was
determined by angiographic measurement criteria from the
North American Symptomatic Carotid Endarterectomy
Trial, with a mean stenosis of 87.3% (range, 60% to 99%).8
In this study group, 40 (28%) patients experienced preop-
erative neurologic symptoms, and 103 (72%) were asymp-
tomatic.
All patients were considered to be high risk for peripro-
cedural complications for CEA. Forty-eight patients were
80 years old, 21 patients presented with restenosis after
carotid endarterectomy, and one additional patient had
restenosis after CAS. Six patients had carotid stenosis after
prior neck surgery with associated irradiation therapy. Oc-
clusion of the contralateral carotid artery was present in 17
patients, 18 patients had severe chronic obstructive pulmo-
nary disease (COPD), and 116 patients were at increased
risk for cardiac complications based on the Eagle criteria
(moderate risk, 108 patients; high risk, 18 patients).9 All
patients had a preoperative ECG in the context of a medical
evaluation. The need for further cardiac work-up, including
echocardiography, stress tests, and cardiac catheterization,
was determined by Eagle criteria and assessment by cardi-
ology and anesthesiology.
Carotid angioplasty and stenting technique. All pa-
tients underwent CAS under local anesthesia, without se-
dation. Vascular surgeons performed the procedures in an
operating room angiography suite with the use of a fixed
imaging system (Siemens AG,Munich, Germany). Femoral
access was used in all cases. Cerebral protection devices
were used in 140 of 143 patients, excluding three patients
who had recent restenosis after CEA (n 2) or CAS (n 1).
These three patients had anatomy that made the risk of
deploying a protection device in the setting of recurrent
stenosis too great. Microporous filters were used in most of
the patients (n  105) and included the EPI FilterWire
(Boston Scientific, Natick, Mass), Accunet (Guidant, Santa
Clara, Calif), and Angioguard (Cordis, Miami, Fla). Tem-
porary balloon occlusion with the PercuSurge GuardWire
(Medtronic, Santa Rosa, Calif) was used in 35 patients.
Once the protection device was deployed, prophylactic
atropine (0.5 to 1.0 mg) was administered as previously
reported.10 For the initial 30 patients treated in the registry,
atropine was administered selectively for the development
of bradycardia with a heart rate 40 beats/min or 50%
change in heart rate. Subsequently, all patients with pri-
mary carotid artery stenosis received a prophylactic dose
before balloon dilatation.
Lesions were predilated with a 4-  40-mm monorail
angioplasty balloon (Long VIVA, Boston Scientific) after
the cerebral protection device was deployed. The type of
neuroprotection device used was based on the clinical trial
protocol or anatomy of the lesion. A self-expanding stent
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included Wallstent (Boston Scientific), Acculink (Guidant),
Precise (Cordis), and NexStent (Endotex, Cupertino, Calif).
Postdilatation was performed with a 5- to 6-  20-mm
monorail balloon (Gazelle, Boston Scientific). Nitroglyc-
erin (100 g) was administered for the treatment of spasm
of the distal internal carotid artery in six cases and was not
associated with hypotension or vasopressor use.
Hemodynamic monitoring. Heart rate and rhythm
were monitored continuously with ECG throughout the
procedure and during the postprocedural period. An auto-
mated cuff inflation sphygmomanometer was used on the
upper arm to measure blood pressure at 5-minute intervals
throughout the procedure and during the postprocedural
period. Continuous blood pressure monitoring was per-
formed during the procedure via the femoral sheath. When
postprocedural hemodynamic considerations, such as vaso-
pressor administration, required continuous arterial pres-
sure monitoring, a radial arterial catheter was placed.
After the procedure, patients were admitted to a step-
down bed for hemodynamic monitoring (heart rate, respi-
ratory rate, and blood pressure) for aminimumof 24 hours.
Patients who received vasopressors were monitored in an
intensive care unit. Postoperative ECG and cardiac isoen-
zymes were obtained for all patients with a history of
coronary artery disease, for those that experienced hemo-
dynamic instability or symptoms suggestive of coronary
ischemia, and in accordance with specific study protocols.
Pharmacologic measures. All patients continued
their -blockers or calcium-channel blockers through the
morning of surgery. Patients received clopidogrel (Plavix,
Sanofi-Synthelabo Pharmaceuticals, New York, NY) before
the CAS procedure and were maintained on clopidogrel for
at least 30 days after the procedure. Patients were given a
loading dose of Plavix consisting of either 75 mg for 5 days
before the procedure or 450 mg 4 hours before the proce-
dure. Intravenous heparin was given intraoperatively to
maintain a target activated clotting time of 250 to 350
seconds.
Intravenous vasoactive agents (phenylephrine or nor-
epinephrine) were used for protracted hypotension that was
not responsive to intravenous fluids. The decision to use
phenylephrine vs norepinephrine was determined in con-
junction with anesthesia. None of the patients required two
vasoactive agents. Blood transfusions were not needed for
any of the patients.
Statistical analysis. Two separate analyses were done
to determine predictors of postoperative hypotension re-
quiring vasopressor support and cardiac morbidity:
1. Patients with postprocedural hypotension requiring
short-duration vasopressor support (24 hours) were
compared with those requiring no vasopressors (0 hours,
including those without postprocedural hypotension).
2. Patients with postprocedural hypotension requiring
prolonged-duration vasopressor support (24 hours)
were compared with those receiving no vasopressors(0 hours) or only short-duration vasopressors (24
hours).
Univariate testing was done by using the Fisher’s exact
test for analysis of dichotomous data and t tests for contin-
uous data analysis. Continuous data are expressed as mean
standard deviation. Significance was assumed at P  .05,
and all tests were two-tailed. A multivariate logistic regres-
sion model with odds ratios (OR) and 95% confidence
intervals (CI) was developed from the results of the univar-
iate analysis, with inclusion variables having a value ofP .05
Dependent variables were either short-duration vaso-
pressor support or prolonged-duration vasopressor sup-
port. Independent variables used in each model were se-
lected from those found to be significant on univariate
analysis (30% vs 5%; no vasopressors vs 24 hours of
vasopressors, respectively). A small number of parameters
were entered into the logistic regression model because the
number of primary and secondary outcomes was small.
Ideally, as other studies have shown, a ratio of events of5
produces unreliable results, whereas a ratio of 10 results
in no major problems.11 Using a large number of parame-
ters in a model with a small number of outcomes produces
confidence intervals that are large and results that are
unreliable. Therefore, intraoperative hypotension was not
added to the model because this was the more obvious
predictor of postoperative vasopressor use. Cardiac out-
comes were analyzed with Fisher’s exact test. Data were
managed and analyzed by SPSS statistical software version
10.1 (SPSS Inc, Chicago, Ill).
RESULTS
CAS was performed successfully in all 143 patients.
Peri- or postprocedural hypotension was seen in 27 patients
(19%). Vasopressor support for postprocedural hypoten-
sion was required in 16 (11%) of 143 patients, with 10 (7%)
requiring 24 hours and 6 (4%) requiring 24 hours of
vasopressors. Postprocedural bradycardia was observed in
16 patients (11%) and was more common in those requir-
ing both short (7/10, P .001) and prolonged (3/6, P
.001) vasopressor support. No patients with postproce-
dural bradycardia required additional atropine administra-
tion or insertion of a temporary pacemaker. The length of
stay did not differ significantly between groups (no vaso-
pressors, 1.4  1.3 days; 1 to 24 hours of vasopressors,
3.6  5.5 days;24 hours of vasopressors, 1.8 0.4 days;
PNS). There were no 30-day ipsilateral cerebral vascular
events or deaths.
Predictors of short-duration vasopressors (<24
hours). Ten patients experienced hypotension that re-
quired vasopressors for 24 hours (mean, 11  3 hours;
range, 6 to 14 hours). These 10 patients (6 men, 4 women)
were a mean age of 70.0  10.1 years, with five having
preoperative neurologic symptoms and a mean stenosis of
91.1%  10.1%.
Univariate analysis of demographic factors demon-
strated that short-duration vasopressor support for hypo-
tension was significantly associated with a history of myo-
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hour of vasopressors, 6/10 [60%]; P  .02) (Table II).
Most of the myocardial infarctions occurred 6 months
before the CAS procedure, and the rate was not signifi-
cantly different between the two groups (no vasopressors,
25/29 vs24 hours of vasopressors, 5/6). The 10 patients
who required short-duration vasopressors, in comparison
with the 127 patients who did not receive vasopressors, had
elevated rates of other comorbidities, including aortic ste-
nosis (30% vs 5%; no vasopressors vs 24 hours of vaso-
pressors, respectively), coronary artery disease (80% vs
63%), recent coronary artery revascularization (20% vs 2%),
and diabetes mellitus (50% vs 25%) without reaching statis-
tical significance (P  NS). The 10 patients who received
short-duration vasopressors had similar rates of renal insuf-
ficiency, smoking history, and high-risk criteria (age 80
years, history of CAS or CEA, neck irradiation, contralat-
eral occlusion, moderate-to-severe cardiac risk, and severe
COPD) compared with the 127 who did not receive vaso-
pressors.
By univariate analysis, intraprocedural factors (Table
II) significantly associated with an increased incidence of
postprocedural hypotension requiring vasopressors for
24 hours included use of the PercuSurge occlusion bal-
loon (P .05), intraprocedural hypotension (P .001), or
intraprocedural use of vasopressors (P  .001). The start-
ing MAP was not predictive of an increased incidence of
postprocedural hypotension requiring vasopressors (no va-
sopressors, MAP  90 mm Hg vs 24 hours of vasopres-
sors, MAP 85 mmHg, PNS). Intraprocedural brady-
cardia was also not associated with an increased incidence of
postprocedural hypotension (P  NS) (Table II). Similarly,
hypotension that required vasopressors for a short duration
was not significantly associated with any particular stent
type (Precise, n  6; Nextstent, n  2; Acculink, n  2)
compared with those requiring no vasopressors (Wallstent,
n  37; Precise, n 23; Nextstent, n 20; Acculink, n
57; P  NS).
Logistic regression multivariate analysis, adjusted for
Table II. Factors associated with need for vasopressor sup
vasopressor support (N  127)
Vasopressor
0 hours,
N  127
N Percent N
Age, Mean  standard deviation 74.6  9.8 7
Female 47 37% 4
History of prior myocardial infarction 29 23% 6
Intraprocedural hypotension 11 9% 8
Intraprocedural radycardia 14 11% 1
Intraprocedural vasopressors 10 8% 8
Use of PeccuSurge occlusion balloon 27 21% 5
OR, odds ratio; CI, confidence interval.
*Multivariate, adjusted for sex and age.age and sex, demonstrated that a prior myocardial infarc-tion (OR, 4.1; 95% CI, 1.0 to 16.4; P .05) was indepen-
dently associated with a need for postprocedural vasopres-
sors for 24 hours (Table II). On multivariate analysis, the
use of the PercuSurge occlusion balloon was not signifi-
cantly associated with an increased likelihood of postproce-
dural vasopressors for 24 hours (OR, 2.9; 95% CI, 0.68
to 12; P  NS).
Predictors of hypotension requiring prolonged
vasopressor support (>24 hours). Six patients experi-
enced hypotension that required vasopressors for 24
hours (mean, 29  4 hours; range, 26 to 36 hours); they
were compared with 137 patients who received no or 24
hours of vasopressor support. Five of the six patients who
required prolonged vasopressors (24 hours) were women
with a significantly higher mean age of 80.8  5.1 years
compared with those who received no or 24 hours of
vasopressor administration (51/137 female; mean age,
74.2  9.8 years; P  .05).
Univariate analysis of demographic factors demonstrated
that patients requiring prolonged vasopressors had rates of
comorbidities including preoperative neurologic symptoms
(17% vs 28%, 24 hours vs 0 to 24 hours, respectively)
history of hypertension (100% vs 88%), myocardial infarc-
tion (26% vs 33%), and diabetes mellitus (33% vs 26%)
similar to patients who required no or 24 hours of vaso-
pressor administration (P  NS). On univariate analysis,
the only high-risk factor associated with risk of hypotension
requiring prolonged vasopressors was age 80 years (0 to
24 hours of vasopressors: 43/137 [31%] vs 24 hours of
vasopressors: 5/6 [83%], P  .02). Otherwise, this group
of patients had similar rates of prior ipsilateral CEA or CAS,
history of neck irradiation, contralateral occlusion, and
moderate (1 or 2 Eagle criteria) or high (3 Eagle criteria)
cardiac risk or severe COPD (P  NS) (Table III).
Intraprocedural factors (Table III) predictive of post-
procedural hypotension requiring prolonged vasopressors
were intraprocedural hypotension (P .001) and intrapro-
cedural bradycardia (P  .03). The starting mean arterial
blood pressure was not predictive of postprocedural hypo-
(1-24 hours, N  10) compared with those requiring no
Univariate Multivariate* OR (CI)
hours,
10
Percent
10.1 NS
40% NS
60% 0.02 0.05* 4.1 (1.0-16.4)
80% 0.001
10% NS
80% 0.001
50% 0.05 0.15* 2.9 (0.68-12.0)port
s
1-24
N 
0.0 tension requiring prolonged vasopressors (no or24 hours
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MAP  85, P  NS). The use of the PercuSurge balloon
and intraprocedural vasopressors also did not significantly
predict postprocedural hypotension requiring prolonged
vasopressors. Similarly, hypotension requiring prolonged
vasopressors was not more common with the use of any
specific stent (Wallstent, n  2; Precise, n  2; Acculink,
n  2) compared with those requiring 0 to 24 hours of
vasopressor support (Wallstent, n  37; Precise, n  17;
NexStent, n  18; Acculink, n  55; P  NS).
Multiple logistic regression multivariate analysis dem-
onstrated that age 80 years (OR, 13.8; 95% CI, 1.5 to
127.2; P  .02) and female sex (OR, 10.9; 95% CI, 1.2 to
100.9; P  .04) were independently associated with post-
procedural hypotension requiring prolonged vasopressors
(24 hours) (Table III).
Cardiac morbidity. Cardiac morbidity was defined as
a periprocedural myocardial infarction, arrhythmias, or
congestive heart failure (Table IV). Three patients (2.1%)
had a periprocedural myocardial infarction, and the risk of
myocardial infarction was not more common in patients
receiving short-duration vasopressors (24 hours, 1/10)
or prolonged vasopressors (24 hours, 0/6) compared
with patients who did not require a vasopressor (1/127,
P  NS). Three patients had a cardiac arrthymia requiring
treatment, and again, the risk of this complication also did
not significantly differ between groups (no vasopressors,
1/127; 24 hours of vasopressors, 1/10; 24 hours va-
sopressors, 0/6; PNS). Finally, the one patient that had
an acute episode of congestive heart failure did not require
Table III. Factors predicting patients requiring 24 hour
24 hours of vasopressors (N  137)
Vasopressors
1-24 hours,
N  137

N Percent N
Age, Mean  standard deviation 74.2  9.8 80
Female 51 37% 5
Age 80 years old 43 31% 5
Intraprocedural hypotension 19 14% 6
Intraprocedural bradycardia 15 11% 3
Intraprocedural vasopressors 18 13% 2
OR, odds ratio; CI, confidence interval.
Table IV. Periprocedural cardiac morbidities after CAS
Vasopressors
Myocardial infarction
N % P value
0 hrs, n  127 2 2%
1-24 hrs, n  10 1 10% NS*
24 hrs, n  6 0 0 NS†
*Comparison on between 0 versus 1-24 hrs of vasopressors.
†Comparison between 0-24 hrs versus 24 hrs of vasopressors.any vasopressors either before or after that episode.DISCUSSION
Improvement in the results of patients treated with
CAS has made it an appealing alternative to CEA, especially
in patients who are at an increased risk for CEA. However,
the increased incidence of stroke and death among patients
80 years old in the Carotid Revascularization Endarter-
ectomy versus Stenting Trial (CREST) lead-in phase has
made some hesitant to perform CAS in these older pa-
tients.12 The primary objective of the current study was to
identify risk factors for hypotension requiring vasopressor
support after CAS. This current study found that hypoten-
sion requiring vasopressor support occurs in a small num-
ber of patients after CAS. In addition, the incidence of
prolonged vasopressor use among older women was in-
creased; however, even though these older women more
frequently required vasopressor use for longer time periods,
this did not lead to a higher rate of cardiac morbidity.
The hemodynamic instability that occurs both during
and after CAS is mediated through the baroreceptors,
which are located in the adventia at the carotid bifurca-
tion.13 These baroreceptors are stimulated by the stretch of
balloon angioplasty, initiating a reflex arc to the nucleus
tractus solitarius via the sinus nerve of Hering, a branch of
the glossopharyngeal nerve. This in turn causes a reciprocal
change in peripheral sympathetic and vagal neural activity
that results in a fall in blood pressure and bradycardia. Stent
placement may promote persistent stimulation of these
baroreceptors.
In this study, two distinct patterns of hypotension
vasopressors (N  6) compared with those requiring 0-
Univariate Multivariate OR (CI)
rs,
6
rcent
5.1 0.02
83% 0.03 0.04 10.9 (1.2-100.9)
83% 0.02 0.02 13.8 (1.5-127.2)
00% .001
50% 0.03
33% NS
Arrhythmia Cardiac heart failure
% P value N % P value
2% 1 1%
4% NS* 0 0 NS*
0% NS† 0 0 NS†s of
24 hou
N 
Pe
.8 
1N
2
1
0appear to be present after CAS. The first pattern involves
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relatively acute period. Patients in whom this develops
experience rapid resolution of the hypotension 24 hours
and frequently 6 hours. These patients, who required a
short duration of vasopressors, had elevated rates of a
history of myocardial infarction. This may be partly ex-
plained by data suggesting increased carotid artery barore-
ceptor sensitivity in patients with coronary artery dis-
ease.14,15 Previous studies have shown that patients with
cardiac risk factors such as coronary artery disease,6 unsta-
ble angina,16 and previous myocardial infarction17 are
more likely to have postprocedural hypotension after CAS.
These studies have shown great variability in duration of
the hypotension, however, and have not specifically exam-
ined predictors of vasopressor use.
The second pattern of hypotension manifested a more
protracted course necessitating vasopressor support. This
pattern appeared to be unrelated to the patients’ underly-
ing cardiac conditions; rather, it may represent a prolonged
reflexive response to which elderly women are more suscep-
tible. Previous studies have found age to be a risk factor for
hemodynamic instability during CAS, which may be related
to dysfunction of baroreceptors.6 In addition, physiologic
changes of older age, including low blood pressure and
age-related ventricular dysfunction, may increase the sus-
ceptibility to hypotension.6 Early reports about CAS dem-
onstrated that older age was a risk factor for postoperative
complications.18-20 In the current study, patients who ex-
perience prolonged hypotension after CAS did not exhibit
any increase in cardiac or other complications. This implies
that while this patient cohort may be more susceptible to
hypotension, the development of hypotension does not
result in an increased risk of adverse consequences.
Intraprocedural hypotension strongly predicted the oc-
currence of postprocedural hypotension both in this cur-
rent study and previous reports.16,17 In a smaller study
involving 51 patients, Qureshi et al17 found that intrapro-
cedural hypotension was the strongest predictor of postpro-
cedural hypotension. Another study found that balloon-
expandable stents with larger final balloon diameters rather
than self-expanding stents were associated with post-CAS
hypotension.16
Limitations of this study include the relatively small
sample size, variation in types of vasopressors used, and
small number of adverse outcomes, which reduces the
number of factors that can be integrated into a multivariate
model. The retrospective review of the data is also a limita-
tion of this study. In addition, because most of the patients
presented with significant comorbidities, distinguishing the
risk factors for hypotension may be more difficult. This
study does, however, re-emphasize the importance of close
hemodynamic monitoring after CAS.
CONCLUSION
Prolonged hypotension requiring vasopressor support
for 24 hours occurs in a minority of patients after CAS,
with a higher incidence in older women. In contrast, hypo-
tension requiring a more limited duration of vasopressoruse occurs more commonly in patients who had a prior
myocardial infarction, independent of age or sex. In the
cohort of patients studied, hypotension that required vaso-
pressors was not associated with an increased incidence of
periprocedural cardiac complications. Continued examina-
tion of these phenomena will help further characterize
which patients can be anticipated to have periprocedural
hemodynamic variability and therefore perhaps require a
more intensive level of observation and or treatment.
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